TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05890157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF
Description: Split mouth randomized clinical trial will be the design of the study. 12 periodontitis patients with 24 opposite shallow periodontal pockets (4-6 mm in depth) will be selected. Randomization in this study will be achieved using toss of coin method in which periodontal pockets were designated either control site or test site. PRF will be used as an adjunct to scaling and root planing to treat the test sites. While control sites will be treated by scaling and root planing only. Clinal periodontal parameters will be recorded and GCF level of PDGF-BB will be measured at baseline and1- and 3- month follow-up visits to evaluate the healing response to the treatment.
Study: NCT05512026

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feasibility Assessment
Description: To validate the performance of the Poseidon System™ for fluid management during water-aided endoscopic procedures in the colon.
Study: NCT05211557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fhB7H3.CAR-Ts
Description: Three dose levels will be evaluated: Dose Level 1 (1×10\^6/kg), dose Level 2 (3×10\^6/kg) and dose Level 3 (5×10\^6/kg). If dose limiting toxicities (DLTs) are observed in each doses, Dose Level -1 (0.5×10\^6/kg /infusion) will be evaluated.~Other Name: B7H3 targeting chimeric antigen receptor T cells Drug: Fludarabine 30 mg/m2 i.v. for 3 consecutive days (Day -5\~Day -3) Other Name: FLUDARA Drug: Cyclophosphamide 750 mg/m2 i.v. for once (Day -5) Other Name: Cytoxan
Study: NCT05449249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long-term fasting
Description: The participants will undergo a fasting program that includes the daily intake of 250 kcal under medical supervision.
Study: NCT05675215

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychopathology screening tests
Description: The assessment phase includes the SCID-5 (First et al., 2017), the D-PSY questionnaire and standardized questionnaires. The D-PSY questionnaire and the SCID-5 (First et al., 2017) will be counterbalanced in terms of the order of administration, with half of the participants taking the SCID-5 (First et al., 2017) first and then the D-PSY questionnaire and the others standardized; the other half will take the D-PSY first and then the SCID-5 (First et al., 2017) and the other questionnaires.~The other standardised questionnaires will be randomised for order of administration. These standardised questionnaires measure social desirability (Balanced Inventory of Desirable Responding, BIDR, Paulhus, 1985, 1991; in French: Cournoyer \& Sabourin, 1991), dissociation (DIS-Q, Vanderlinden et al., 1993), phobia (the Fear Questionnaire, F.Q., Marks \& Mathews, 1979; in French Cottraux et al., 1987) and autism (AQ, Baron-Cohen et al., 2001; in French, translation by Braun \& Kempenaers, 2007).
Study: NCT05412914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam infusion
Description: Remimazolam infusion for anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion
Description: Propofol infusion for anesthesia induction
Study: NCT04765280

Intervention type: DIAGNOSTIC_TEST
Intervention: Central sensitization inventory
Description: Standardized questionnaire to determine the level of central sensitization. Patients with a score of 40 and above are considered to have central sensitization.

Intervention type: OTHER
Intervention: Short form-36
Description: Standardized questionnaire to investigate the quality of life in patients. The score of the scale is between 0-100. The higher scores are associated with greater deterioration in quality of life.

Intervention type: OTHER
Intervention: Istanbul Low Back Pain Disability Index
Description: Standardized questionnaire to investigate the disability in patients with low back pain. The score of the scale is between 0-90. It is accepted that the higher the score, the higher the disability.

Intervention type: OTHER
Intervention: Disabilities of the Arm, Shoulder and Hand (DASH)
Description: Standardized questionnaire to investigate the disability in patients with upper extremity musculoskeletal disorders. The score of the scale is between 0-100 It is accepted that the higher the score, the higher the disability.

Intervention type: OTHER
Intervention: Neck Pain and Disability scale
Description: Standardized questionnaire to investigate the disability in patients with neck pain. The score of the scale is between 0-100. It is accepted that the higher the score, the higher the disability.

Intervention type: OTHER
Intervention: Knee Injury and Osteoarthritis Outcome Score
Description: Standardized questionnaire to investigate the disability in patients with knee pain. The score of the scale is between 0-100It is accepted that the higher the score, the higher the disability.

Intervention type: OTHER
Intervention: Western Ontario and McMaster Universities Arthritis Index
Description: Standardized questionnaire to investigate the disability in patients with hip osteoarthritis. The score of the scale is between 0-240. It is accepted that the higher the score, the higher the disability.

Intervention type: OTHER
Intervention: Visual analogue scale
Description: global pain score on a 0 to 10
Study: NCT05941819

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARC-IM Thoracic System implantation
Description: Implantation of the ARC-IM Thoracic Lead on the low thoracic level of the spinal cord and implantation of the ARC-IM IPG in the abdominal region
Study: NCT05894954

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Precision Medicine Approach
Description: Precisions Medicine Approach involves a combination of medicines, dietary supplements, lifestyle changes, and diagnostics

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises
Description: Tailored Medications and Devices to address imbalances per lab results, known to affect cognitive function:~Potential Devices: Oura Ring, Continuous Glucose Monitor, Keto-Mojo, and Heartmath Inner Balance. Few may receive Hyperbaric Oxygen Treatment, neurostimulation, neurofeedback, neurostimulation to reduce stress and relax the body), photobiomodulation (light therapy), or CPAP.~Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.~Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine Penicillin G, Methylene Blue, Nystatin, Clotrimazole, Metronidazole, Valacyclovir, Acyclovir, Famciclovir, Shingles Vaccine Vascular treatments may include: antihypertensives, Ubrelvy, aspirin, Eliquis

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: Participate in cognitively stimulating and social activities, exercise, sleep, control risk factors, adhere to a health diet, consult physician if conditions worsen

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle including diet, exercise, stress management
Description: Combining a tailored diet, exercise and stress management program supported by coaching specialists
Study: NCT05278182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule
Description: Patients with acute myocardial infarct on the basis of optimal medical therapy will take Naoxintong capsules following directions for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with acute myocardial infarct on the basis of optimal medical therapy will take placebo following directions for 12 months
Study: NCT04428801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose-derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: autologous adipose-derived stem cells
Description: Culture expanded mesenchymal stem cells isolated from a patient's own abdominal fat tissue
Study: NCT05048160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Description: Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
Study: NCT05771727

Intervention type: OTHER
Intervention: survey
Description: The 55-item survey created by the researchers was applied online to determine the psychological and physical effects of COVID-19 on neuromuscular patients and their families. This survey also included the Content of the 9-Item Caregiver COVID-19 Limitations Scale (CCLS-9).
Study: NCT05730595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymph node dissection
Description: The extent of lymph node dissection varies between groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymph node dissection
Description: The extent of lymph node dissection varies between groups
Study: NCT06100575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website (www.mee-leven.be)
Description: The tool is a website aimed siblings and children of someone who has suicidal thoughts and/or behaviors. The intended objectives of the tool are 1) to contribute to knowledge about suicide and health care options, 2) to increase perceived competences in dealing with suicidality of a family member, 3) to reduce perceived pressure and negative feelings such as hopelessness and 4) to be accessible and user-friendly.~These objectives are achieved by providing the following content: 1) concerning the sibling/child themselves (primary objective) : information about the potential impact of having a suicidal family member, own needs, informal and formal (self) care, dealing with the suicidal family member, dealing with other family members 2) concerning the suicidal family member (Secondary objective): information about the suicidal process, signal recognition, how to provide support/create a safe environment for suicidal loved ones , help available for suicidal relatives
Study: NCT06131619

Intervention type: OTHER
Intervention: assesment of cognitive parameters with DLOTCA-G
Description: All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.

Intervention type: OTHER
Intervention: assesment of cognitive parameters with DLOTCA-G
Description: All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.

Intervention type: OTHER
Intervention: assesment of cognitive parameters with DLOTCA-G
Description: All three groups were evaluated once with the DLOTCA-G, a cognitive assessment battery.
Study: NCT04911010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: In the intervention condition, patients are treated with prolonged exposure in 16 hours of individual therapy immediately after the baseline measurement. The 16 individual therapeutic sessions take place 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapeutic sessions are recorded on video with camera focus on the therapist. Parts of the prolonged exposure procedure (reliving the traumatic memory) are recorded on tape (via the patient's personal smartphone) so that the patient can listen to the recording as homework at home. The patients then take part in a post-treatment study diagnosis (T1).
Study: NCT05077488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLIFT™ with Lidocaine
Description: Sterile gel in disposable syringe
Study: NCT05630157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unplugged plus gambling component
Description: 12 units/lessons of the Unplugged prevention curriculum plus a gambling component including specific gambling contents in units 3-4-5-7-9 and a 13th unit based on probability and mathematical concepts taught through an online simulator
Study: NCT05713864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPM-6000UF
Description: The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.
Study: NCT06358222

Intervention type: PROCEDURE
Intervention: Blood ctDNA + methylation + PET-CT and Postoperative pathology
Description: A highly sensitive tumor-naïve MRD panel of ctDNA will be employed to detect preoperative blood. Some patients will undergo methylation profiling to prospectively establish LNMs-specific ctDNA methylation signatures.

Intervention type: PROCEDURE
Intervention: MRD+ methylation (or combined with PET-CT) and Invasive mediastinoscopy /EBUS-TBNA
Description: A certain number (depending on the Results of Stage 1) of patients requiring invasive mediastinoscopy or EBUS-TBNA, based on the clinical guidelines, will be included for blood ctDNA mutation/methylation profile (or combined PET-CT), and the detection rate of LNMs will be assessed in patients with negative preoperative blood ctDNA mutation/methylation (or combined PET-CT). The accuracy of predicting LNMs will be compared with that of patients with negative or positive preoperative blood ctDNA mutation/methylation (or combined PET-CT).

Intervention type: PROCEDURE
Intervention: Intraoperative lymph node dissection
Description: For patients with negative preoperative blood negative testing (ctDNA mutation/methylation profiles alone or in combination with PET-CT), systematic lymph node sampling/dissection and no lymph node dissection will be grouped and compared. Regular follow-up is performed to investigate the impact on long-term MRD negative duration and prognosis.
Study: NCT06088420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .
Description: Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .
Description: Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .
Description: Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .
Study: NCT06705140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose (LD) RSVt vaccine
Description: Pharmaceutical form:~Liquid for nasal spray~Route of administration: Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose (SD) RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard Dose (SD) RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose (HD) RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose (HD) RSVt vaccine
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal
Study: NCT06712901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Median Ranked Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were median ranked in the prior study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overall Preferred Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by all participants in the prior study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black American Preferred Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by Black participants but not White participants in the prior study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: White American Preferred Cancer Screening Messaging
Description: Strong message content that increases screening and sharing intentions. Messages in this intervention were highly rated messages by White participants but not Black participants.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: There will be no message content of cancer screening and sharing intentions in this arm.
Study: NCT06711926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distilled water
Description: Participants will receive 600ml distilled water with a strawberry flavour, in four equal aliquots across 30 minutes (150ml every 7.5minutes)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-skimmed milk
Description: Participants will receive \~600ml semi-skimmed milk with a strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey permeate
Description: Participants will receive \~600ml whey permeate (30g sachet, rehydrated with distilled water)with strawberry flavour in four equal aliquots across 30minutes (150ml every 7.5minutes).
Study: NCT06719141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP352
Description: LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube.
Study: NCT06728254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medication management
Description: The test system consists of:~* Linked care platform (backend) which provides a new possibility of data exchange for IT systems of caregivers, pharmacies, and GPs~* User interfaces for caregivers as well as for the systems myneva.carecenter and mynevaTOgo~* An extension of the user interface for GPs in their IT system (in the test only for the physician software PCPO by CompoGroup Medical )~* An extension of the user interface for pharmacists in their IT system (in the test only for pharmacies with software from Apothekerverlag)~Functionally, the solution should, coordinate the medication requirements between pharmacies, GPs, and caregivers (subarea medication).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: Usual care.
Study: NCT06743191

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Access Nourish
Description: A total of 65 participants with hypertension and low access to high quality food will be enrolled to test the feasibility of using commercially available grocery delivery services, simultaneous to a robust behavioral intervention, to improve adherence to the DASH eating pattern. The behavioral intervention will include skills training, nutrient goal setting, self-monitoring via dietary tracking, personalized text message feedback, and adaptive health coaching. Participants will also receive a membership to Instacart+ and weekly grocery list recommendations from a health coach. Participants will be able to complete all intervention components via smartphone. The intervention period for participants will be 4 months.
Study: NCT06750432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMN310
Description: A humanized immunoglobulin G1 (IgG1) monoclonal antibody
Study: NCT04846361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal hygiene wash
Description: vaginal hygiene wash containing Propylene Glycol, Ethylhexylglycerin, Lactic Acid, Sodium Pyrrolidone Carboxylic Acid, Alpha-Glucan Oligosaccharide, Lactococcus Ferment Lysate, Octenidine Hydrochloride plus all other ingredients in placebo wash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo wash
Description: placebo wash containing water, disodium cocoamphodiacetate, sodium chloride, sodium glycolate, acrylates copolymer, potassium laureate phosphate, tripotassium phosphate, laurel glucoside, lauramidopropyl hydroxysultaine, disulfonate de sodium, Polyethylene glycol (PEG)-120 Methyl Glucose Trioleate, Propanediol, Glycol distearate, Laureth-4, Cocamidopropyl betaine, Potassium Lactate, Caprylyl Glycol, Disodium ethylenediaminetetraacetic acid (EDTA), Potassium Hydroxide, and Perfume
Study: NCT05252793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education based on the health belief model
Description: After the intervention, it is expected that the scores of the patients on the healthy lifestyle behaviors scale will increase.